Low-Dose Involved Field Radiation after Chemotherapy in Advanced Hodgkin Disease A Southwest Oncology Group Randomized Study

• Objective: To determine if low-dose involved field radiation after complete remission induction with chemo-tnerapy is effective in preventing relapse and improving survival in patients with stage III or IV Modgkin disease. • Design: A randomized controlled trial with a median follow-up time of 8.1 years. • Setting: A Southwest Oncology Group multi-institutional study. Patients were entered from univer-sity- and community-based practices. • Patients: 278 adults with clinical or pathologic stage III or IV Hodgkin disease, who achieved complete responses after 6 cycles of MOP-BAP (nitrogen mus-tard, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine) and who agreed to be randomly assigned to either radiation or no further treatment. • Intervention: Patients were assigned to either no further treatment or low-dose radiation to all initially involved sites (radiation dose, 2000 cGy to lymph node areas and 1000 to 1500 cGy to other involved organ sites). • Measurements: Differences in remission duration, relapse-free survival, and survival